An effective double action formulation to relieve both dry cough and nasal symptoms1,2

iNova Pharmaceuticals has launched an exciting new product to their cough portfolio, adding to their well-established range of dry and wet cough relief options. Pholtex, South Africa’s number one prescribed dry cough brand, is proud to announce the launch of Pholtex Plus 2,3.

Pholtex Plus is an effective double action formulation to relieve a dry cough and a blocked nose 2; common complaints associated with viral upper respiratory infections, Allergic rhinitis and Post-nasal drip4, 5.  Pholtex Plus contains Pholcodine and Phenylephrine Hydrochloride, the only combination of its kind on the South African market 1,2.

Pholcodine acts directly on the cough centre of the brain (in the medulla) to suppress a dry cough and provide day and night time relief. Pholcodine has little, if any analgesic or euphoriant effects, is generally non-constipating and is non-habit forming. In fact, 10mg of Pholcodine is equipotent to 15 mg codeine in suppressing a cough6,7.

Phenylephrine hydrochloride is a selective alpha sympathomimetic that provides effective relief of nasal congestion associated with the common cold, within as little as 15-30 minutes8. Phenylephrine has been used internationally as a nasal decongestant for more than 70 years and has a well-established efficacy and safety profile 4,8,9.

Pholtex Plus will be available at leading pharmacies countrywide from May 2018 and is available in both a 100 ml and 200 ml pack sizes.

Many people have trouble differentiating between these two types of coughs, and end up using the incorrect treatments, causing their cough to remain untreated for longer than necessary10.

iNova is also launching a consumer website to educate patients about the difference between a wet and dry cough, their respective symptoms and how to treat each cough effectively.

Please visit iNova Pharmaceuticals at for more information.

Name and business address of applicant: iNova Pharmaceuticals (Pty) Limited. Co. Reg. No.1952/001640/07, 15E Riley Road, Bedfordview. Tel. No. 011 087 0000. For full prescribing information, refer to the individual package inserts as approved by the Medicines Control Council (MCC). Further information is available on request from iNova Pharmaceuticals.


  1. South African Medicine Price Registry. Database of Medicine Prices. [Online] 2018 February 24 [cited 2018 March 12]; Available at URL:
  2. Pholtex Plus approved package insert.
  3. Impact Rx. Script data – January 2017.
  4. Consolini DM. Cough in Children. Merck Manual Professional Version [online] Aug 2016 [cited 20 Feb 2018]; Available from URL:
  5. Fried MP. Nasal Congestion and Rhinorrhea. Merck Manual Professional Version [online] March 2016 [cited 20 Feb 2018]; Available from URL:,-nose,-and-throat-disorders/approach-to-the-patient-with-nasal-and-pharyngeal-symptoms/nasal-congestion-and-rhinorrhea.
  6. Girdwood RH, editor. Clinical pharmacology. 25th edition. Edinburgh: Bailliere Tindall; 1985. p. 328.
  7. Equinozzi R, Robuschi M, on behalf of the Italian Investigational Study Group on Pholcodine in Acute Cough. Comparative efficacy and tolerability of pholcodine and dextromethorphan in the management of patients with acute, non-productive cough. A randomized, double-blind, multicenter study. Treat Respir Med 2006;5(6):509-513.
  8. Kollar C, Schneider H, Waksman J, et al. Meta-Analysis of the Efficacy of a Single Dose of Phenylephrine 10 mg Compared with Placebo in Adults with Acute Nasal Congestion Due to the Common Cold. Clin Ther 2007;29(6):1057-1070.
  9. Consumer Healthcare Products Association. Briefing Book. Meeting of the Nonprescription Drugs Advisory Committee December 2007 [Docket No. 2007P-0047] [online] [cited 20 Feb 2018]; Available from URL:
  10. Differentiating Dry Cough and Wet Cough Based on Causes, Symptoms, Treatment  – ePainAssist ( Website accessed on 11 March 2018